Showing results (41-50 of 183) with videos related to
Sort By:
Pageof 19
HIV Clinical Trials|January 14, 2017
Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudyMaria Saumoy, Juan M Tiraboschi, Jordi Ordoñez-Llanos, et al.The Journal of Antimicrobial Chemotherapy|September 28, 2015
Clinical progression of severely immunosuppressed HIV-infected patients depends on virological and immunological improvement irrespective of baseline statusElena Ferrer, Jordi Curto, Anna Esteve, et al.BMC Infectious Diseases|June 27, 2015
Prevalence of methicillin-resistant Staphylococcus aureus colonization in HIV-infected patients in Barcelona, Spain: a cross-sectional studyArkaitz Imaz, Mariana Camoez, Silvana Di Yacovo, et al.Antiviral Therapy|March 9, 2005
Early virological failure with a combination of tenofovir, didanosine and efavirenzDaniel Podzamczer, Elena Ferrer, Josep Maria Gatell, et al.Journal of Neurovirology|March 16, 2018
Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39)Arkaitz Imaz, Jordi Niubó, Alieu Amara, et al.Pharmacogenetics and Genomics|May 20, 2016
HLA-B*57: 01 genotyping in the prevention of hypersensitivity to abacavir: 5 years of experienceCristina Ruiz-Iruela, Núria Padullés-Zamora, Daniel Podzamczer-Palter, et al.Journal of the International AIDS Society|November 14, 2014
Long-term fat redistribution in ARV-naïve HIV+ patients initiating a non-thymidine containing regimen in clinical practiceElena Ferrer, Antonio Navarro, Jordi Curto, et al.AIDS Research and Human Retroviruses|December 1, 2010
Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patientsJosé R Santos, Josep M Llibre, Pere Domingo, et al.Journal of the International AIDS Society|November 15, 2014
DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTISilvana Di Yacovo, Jose Molto, Elena Ferrer, et al.AIDS (London, England)|December 15, 2010
A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected populationMark Nelson, Hans-Jürgen Stellbrink, Daniel Podzamczer, et al.Pageof 19